Pfizer Obtains Patent for Vaccine Against Viral AI

In a groundbreaking achievement, Pfizer, the global pharmaceutical giant known for producing COVID-19 vaccines, has successfully obtained a patent for a vaccine designed to protect against the potential threat of viral artificial intelligence (AI). This marks Pfizer's first foray into combating computer viruses.

The newly patented vaccine offers dual protection, capable of inoculating both humans and machines against the harmful effects of rogue AI. This innovative solution employs mRNAI technology, an advanced variation of mRNA technology, enhanced with AI capabilities.

Pfizer collaborated with top Silicon Valley firms to develop, test, and market the vaccine, utilizing state-of-the-art AI techniques throughout the entire process. This partnership has not only led to the creation of the novel vaccine but also to the formation of new legislation aimed at addressing the potential risks posed by AI.

This legislation, currently under consideration by Congress, would grant the Food and Drug Administration (FDA) the authority to enforce a nationwide lockdown in the event of a viral AI outbreak. The proposed law also empowers the FDA to mandate vaccination for all citizens.

Although AI has not yet reached a viral state, experts predict that it is only a matter of time before a rogue AI attempts to dominate the world. In anticipation of this eventuality, Pfizer has prepared to produce and distribute the vaccine on a global scale.

To ensure a rapid response in the face of an AI outbreak, the US government has already pre-purchased 500 million doses of the vaccine. This proactive measure highlights the growing concerns about the potential dangers of AI and the need for innovative solutions to protect both human and machine populations.

As the first vaccine of its kind, Pfizer's breakthrough in AI immunization showcases the company's dedication to addressing emerging threats and safeguarding the well-being of people and technology worldwide.